<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatrics. Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Pediatrics. Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Педиатрия. Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2658-6630</issn><issn publication-format="electronic">2658-6622</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">636903</article-id><article-id pub-id-type="doi">10.26442/26586630.2024.3.202961</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Paracetamol is both a friend and a foe: What should a pediatrician know? A clinical case</article-title><trans-title-group xml:lang="ru"><trans-title>Парацетамол – и друг, и враг: что должен знать педиатр? Клинический случай</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4200-4598</contrib-id><name-alternatives><name xml:lang="en"><surname>Zakharova</surname><given-names>Irina N.</given-names></name><name xml:lang="ru"><surname>Захарова</surname><given-names>Ирина Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф., зав. каф. педиатрии им. акад. Г.Н. Сперанского, засл. врач России</p></bio><email>zakharova-rmapo@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2847-6268</contrib-id><name-alternatives><name xml:lang="en"><surname>Berezhnaya</surname><given-names>Irina V.</given-names></name><name xml:lang="ru"><surname>Бережная</surname><given-names>Ирина Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доц. каф. педиатрии им. акад. Г.Н. Сперанского</p></bio><email>berezhnaya-irina26@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2861-5619</contrib-id><name-alternatives><name xml:lang="en"><surname>Sugian</surname><given-names>Narine G.</given-names></name><name xml:lang="ru"><surname>Сугян</surname><given-names>Нарине Григорьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доц. каф. педиатрии им. акад. Г.Н. Сперанского, зам. глав. врача</p></bio><email>narine6969@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian Medical Academy of Continuous Professional Education</institution></aff><aff><institution xml:lang="ru">ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Khimki Hospital</institution></aff><aff><institution xml:lang="ru">ГБУЗ МО «Химкинская больница»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-11-01" publication-format="electronic"><day>01</day><month>11</month><year>2024</year></pub-date><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>223</fpage><lpage>229</lpage><history><date date-type="received" iso-8601-date="2024-10-10"><day>10</day><month>10</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-10-10"><day>10</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://pediatria.orscience.ru/2658-6630/article/view/636903">https://pediatria.orscience.ru/2658-6630/article/view/636903</self-uri><abstract xml:lang="en"><p>One of the most common drug-related side effects is hepatotoxicity. The most common cause of severe drug-induced liver injury is acetaminophen (paracetamol), as it is an over-the-counter drug. Paracetamol is safe and effective in children and adolescents at therapeutic doses; however, it is the leading cause of acute liver failure in children (21% of cases) and adults (40%) with overdose. The clinical presentation of toxic liver damage depends on the time elapsed after taking paracetamol and its dose. Symptoms of liver damage are not always obvious but can develop rapidly from day 2 to day 5 after poisoning. The article presents a clinical case of an unintentional overdose of paracetamol in a teenage girl due to non-compliance with the dose and regimen.</p></abstract><trans-abstract xml:lang="ru"><p>Одним из наиболее распространенных побочных эффектов, связанных с приемом лекарственных средств, является гепатотоксичность. Наиболее часто тяжелое лекарственное поражение печени вызывает ацетаминофен (парацетамол), поскольку относится к категории безрецептурных препаратов. Парацетамол – безопасное и эффективное средство у детей и подростков при применении в терапевтических дозах, но, с другой стороны, является наиболее распространенной причиной острой печеночной недостаточности у детей (21% случаев) и взрослых (40%) при передозировке. Клиническая картина токсического поражения печени зависит от прошедшего после приема парацетамола времени и его количества. Симптомы поражения печени не всегда очевидны, но могут стремительно развиться со 2 по 5-е сутки после отравления. В статье приведено клиническое наблюдение непреднамеренной передозировки парацетамола у девочки-подростка при несоблюдении дозы и режима приема.</p></trans-abstract><kwd-group xml:lang="en"><kwd>drug-induced liver injury</kwd><kwd>hepatotoxicity</kwd><kwd>paracetamol</kwd><kwd>acetaminophen</kwd><kwd>paracetamol overdose</kwd><kwd>poisoning</kwd><kwd>dose-sparing effect</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>лекарственное поражение печени</kwd><kwd>гепатотоксичность</kwd><kwd>парацетамол</kwd><kwd>передозировка парацетамола</kwd><kwd>ацетаминофен</kwd><kwd>отравление</kwd><kwd>дозосберегающий эффект</kwd></kwd-group><funding-group><funding-statement xml:lang="en">This study was supported by Dr. Reddy´s Laboratories Ltd.</funding-statement><funding-statement xml:lang="ru">Материал подготовлен при финансовой поддержке компании Д-р Редди’с Лабораторис Лтд.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Mulchandani R, Kakkar AK. Reporting of adverse drug reactions in India: A review of the current scenario, obstacles and possible solutions. Int J Risk Saf Med. 2019;30(1):33-44. DOI:10.3233/JRS-180025</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Tantikul C, Dhana N, Jongjarearnprasert K, et al. The utility of the World Health Organization-The Uppsala Monitoring Centre (WHO-UMC) system for the assessment of adverse drug reactions in hospitalized children. Asian Pac J Allergy Immunol. 2008;26(2-3):77-82.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Shukla AK, Jhaj R, Misra S, et al. Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions. J Family Med Prim Care. 2021;10(9):3303-8. DOI:10.4103/jfmpc.jfmpc_831_21</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. 2014;22(2):83-94. DOI:10.1016/j.jsps.2013.02.003</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Srisuriyachanchai W, Cox AR, Jarernsiripornkul N. Patients’ Identification, Management and Prevention of Adverse Drug Reactions: A Cross-Sectional Survey of Patients with Severe Adverse Drug Reactions. J Clin Med. 2024;13(14):4165. DOI:10.3390/jcm13144165</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Mt M, Ss J, Plgc L, Tghk S. Prevalence, Characteristics and Factors Associated with Adverse Drug Reactions Among Hospitalized Patients. Hosp Pharm. 2024;59(4):489-97. DOI:10.1177/00185787241234217</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Ивашкин В.Т., Барановский А.Ю., Райхельсон К.Л., и др. Лекарственные поражения печени (клинические рекомендации для врачей). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(1):85-115 [Ivashkin VT, Baranovsky AYu, Raikhelson KL, et al. Drug-Induced Liver Injuries (Clinical Guidelines for Physicians). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(1):85-115 (in Russian)]. DOI:10.22416/1382-4376-2019-29-1-101-131</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Bessone F, Hernandez N, Tagle M, et al. Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver. Ann Hepatol. 2021;24:100321. DOI:10.1016/j.aohep.2021.100321</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Aithal G, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806-15. DOI:10.1038/clpt.2011.58</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Dijmărescu I, Guţă OM, Brezeanu LE, et al. Drug-Induced Hepatitis in Children: The Experience of a Single Center in Romania. Children (Basel). 2022;9(8):1136. DOI:10.3390/children9081136</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Bunchorntavakul C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther. 2013;37(1):3-17. DOI:10.1111/apt.12109</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ostapowicz G, Fontana RJ, Schiødt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947-54. DOI:10.7326/0003-4819-137-12-200212170-00007</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Green C, Krafft H, Guyatt G, Martin D. Symptomatic fever management in children: A systematic review of national and international guidelines. PLoS One. 2021;16(6):e0245815. DOI:10.1371/journal.pone.0245815</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Björnsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol. 2015;89(3):327-34. DOI:10.1007/s00204-015-1456-2</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Романов Б.К., Олефир Ю.В., Аляутдин Р.Н., и др. Безопасность применения лекарственных средств у детей – данные международного мониторинга за 50 лет. Безопасность и риск фармакотерапии. 2019;7(2):57-64 [Romanov BK, Olefir YuV, Alyautdin RN, et al. Drug Safety for Children — International Monitoring Data for 50 Years. Safety and Risk of Pharmacotherapy. 2019;7(2):57-64 (in Russian)]. DOI:10.30895/2312-7821-2019-7-2-57-64</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Лукина М.В., Андрущишина Т.Б., Дронов И.А., и др. Данные о безопасности применения парацетамола во время беременности. Вопросы гинекологии, акушерства и перинатологии. 2020;19(6):96-101 [Lukina MV, Andrushchishina TB, Dronov IA, et al. Safety of paracetamol during pregnancy: literature review. Problems of Gynecology, Obstetrics and Perinatology. 2020;19(6):96-101 (in Russian)]. DOI:10.20953/1726-1678-2020-6-96-101</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guideline Panel: Chair; Panel members; EASL Governing Board representative. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222-61. DOI:10.1016/j.jhep.2019.02.014</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Rowden AK, Norvell J, Eldridge DL, Kirk MA. Updates on acetaminophen toxicity. Med Clin North Am. 2005;89(6):1145-59. DOI:10.1016/j.mcna.2005.06.009</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Prescott LF. Gastrointestinal absorption of drugs. Med Clin North Am. 1974;58(5):907-16. DOI:10.1016/s0025-7125(16)32088-0</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Lee WM. Acetaminophen (APAP) hepatotoxicity-Isn’t it time for APAP to go away? J Hepatol. 2017;67(6):1324-31. DOI:10.1016/j.jhep.2017.07.005</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Ishitsuk Y, Kondo Y, Kadowaki D. Toxicological properties of acetaminophen: dark side of a safe antipyretic/analgesic drug? Biol Pharm Bull. 2020;43:195-206. DOI:10.1248/bpb.b19-00722</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>McGill MR, Jaeschke H. Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis. Pharm Res. 2013;30(9):2174-87. DOI:10.1007/s11095-013-1007-6</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Yoon E, Babar A, Choudhary M, et al. Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update. J Clin Transl Hepatol. 2016;4(2):131-42. DOI:10.14218/JCTH.2015.00052</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Jaeschke H, Williams CD, Ramachandran A, Bajt ML. Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int. 2012;32(1):8-20. DOI:10.1111/j.1478-3231.2011.02501.x</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Hossen MS, Akter A, Azmal M, et al. Unveiling the molecular basis of paracetamol-induced hepatotoxicity: Interaction of N-acetyl-p-benzoquinone imine with mitochondrial succinate dehydrogenase. Biochem Biophys Rep. 2024;38:101727. DOI:10.1016/j.bbrep.2024.101727</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Lee H, Yang X, Jin PR, et al. The Discovery of Gut Microbial Metabolites as Modulators of Host Susceptibility to Acetaminophen-Induced Hepatotoxicity. Drug Metab Dispos. 2024;52(8):754-64. DOI:10.1124/dmd.123.001541</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Van der Marel CD, Anderson BJ, van Lingen RA, et al. Pharmacokinetics of paracetamol and metabolites in infants. Eur J Clin Pharmacol. 2003;59;243-51. DOI:10.1007/s00228-003-0608-0</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Guo W, Liu J, Sun J, et al. Butyrate alleviates oxidative stress and regulates NRF2 nuclear accumulation and H3K9/14 acetylation via GPR109A in bovine mammary and breast epithelial cells. Free Radical Biol Med. 2020;152:728-42.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Gamal W, Treskes P, Samuel K, et al. Low-dose acetaminophen induces early disruption of cell-cell tight junctions in human hepatic cells and mouse liver. Sci Rep. 2017;7:37541. DOI:10.1038/srep37541</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Wong A, Graudins A. Risk prediction of hepatotoxicity in paracetamol poisoning. Clin Toxicol (Phila). 2017;55(8):879-92. DOI:10.1080/15563650.2017.1317349</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Мельникова Л.И., Ильченко Л.Ю., Дунаева Е.А., и др. Выявление синдрома Жильбера методом пиросеквенирования у пациентов в реальной практике. Архивъ внутренней медицины. 2019;9(6):475-82 [Melnikova LI, Ilchenko LYu, Dunaeva EA, et al. Diagnosis of gilbert’s syndrome via pyrosequencing in clinical practice. The Russian Archives of Internal Medicine. 2019;9(6):475-82 (in Russian)]. DOI:10.20514/2226-6704-2019-9-6-475-482</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Лужников Е.А., Суходолова Г.Н. Педиатрическая клиническая токсикология. Ростов н/Д: Феникс, 2013 [Luzhnikov EA, Sukhodolova GN. Pediatricheskaia klinicheskaia toksikologiia. Rostov-na-Donu: Feniks, 2013 (in Russian)].</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950-66. DOI:10.1038/ajg.2014.131</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology. 2014;60(4):1399-408. DOI:10.1002/hep.27317</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Kesar V, Channen L, Masood U, et al. Liver Transplantation for Acute Liver Injury in Asians Is More Likely Due to Herbal and Dietary Supplements. Liver Transpl. 2022;28(2):188-99. DOI:10.1002/lt.26260</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Захарова И.Н., Бережная И.В., Сугян Н.Г., и др. Лечение лихорадки при острых респираторных инфекциях верхних дыхательных путей у детей. Медицинский совет. 2022;16(1):88-95 [Zakharova IN, Berezhnaya IV, Sugyan NG, et al. Treatment of fever in acute upper respiratory tract infections in children. Medical Council. 2022;16(1):88-95 (in Russian)]. DOI:10.21518/2079-701X-2022-16-1-88-95</mixed-citation></ref></ref-list></back></article>
